AL Amyloidosis
                   
Revised Mayo Clinic AL Amyloidosis Staging System  
Staging system for newly-diagnosed light-chain amyloidosis, incorporating serum free light chains  
           
           
  Value Points     1. Sum the number of risk factors    
Difference between serum free kappa and lambda light chains (mg/L)     Difference between serum free kappa and lambda light chains:  < 180 mg/L  180 mg/L or higher  
Troponin T (cTNT), ng/L     Troponin T (cTNT):  < 25 ng/L  25 ng/L or higher    
NT-proBNP, ng/L     NT-proBNP:  < 1800 ng/L (< 213 pmol/L)  1800 ng/L (213 pmol/L) or higher    
                   
          2. Determine prognostic stage Number of risk factors:  
          Risk factors Revised Prognostic Stage Median OS (months)1 Five-year survival1  
Sum of score       0 I 94 59%  
Risk category       1 II 40 42%  
          2 III 14 20%  
          3 IV 6 14%  
         
Reference  
Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012 Mar 20;30(9):989-95. doi: 10.1200/JCO.2011.38.5724. Epub 2012 Feb 13.